Washington University Infusion Center Pharmacy

St Louis, Missouri 63110

1 studies enrolling now · 11 studies all time

What they study most

Advanced, Androgen Receptor Positive Triple Negative Breast Cancer, BRAF V600E-mutant Metastatic Colorectal Cancer, Breast Cancer, CD33 Positive Acute Myelogenous Leukemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell of Head and Neck, Genes, BRCA 1, Locally Advanced Solid Tumors, Locally Advanced or Metastatic Solid Tumors, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Studies at this site

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements — Recruiting now
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer — Completed
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) — Completed
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer — Completed
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC — Stopped early
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors — Stopped early
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC — Completed
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab — Completed
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy — NO_LONGER_AVAILABLE
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer — Completed